Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL635171 | 1.00 | UTS2R (0.71) | UTS2RTNF | |
| SCHEMBL635888 | 0.97 | UTS2R (0.70) | UTS2RTNF | |
| SCHEMBL635889 | 0.97 | UTS2R (0.70) | UTS2RTNF | |
| SCHEMBL2345909 | 0.92 | UTS2R (0.72) | UTS2R | |
| SCHEMBL2343966 | 0.92 | UTS2R (0.71) | UTS2R | |
| SCHEMBL2345910 | 0.90 | UTS2R (0.76) | UTS2R | |
| SCHEMBL14949848 | 0.90 | UTS2R (0.68) | UTS2R | |
| SCHEMBL28783202 | 0.90 | UTS2R (0.68) | UTS2R | |
| SCHEMBL2341361 | 0.89 | UTS2R (0.72) | UTS2R | |
| SCHEMBL2345723 | 0.89 | UTS2R (0.80) | UTS2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9079896-B2 | Urotensin II receptor antagonists | JANSSEN PHARMACEUTICA NV (BE) | 2015-07-14 | — | — | US | disclosed |
| US-8445514-B2 | Urotensin II receptor antagonists | JANSSEN PHARMACEUTICA N.V. (BE) | 2013-05-21 | — | — | US | disclosed |
| US-8445514-B2 | Urotensin II receptor antagonists | JANSSEN PHARMACEUTICA N.V. (BE) | 2013-05-21 | — | — | US | disclosed |
| EP-2326644-B1 | UROTENSIN II RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2012-02-22 | — | — | EP | disclosed |
| US-20110269768-A1 | UROTENSIN II RECEPTOR ANTAGONISTS | KINNEY WILLIAM A | 2011-11-03 | — | — | US | disclosed |
| US-20110269768-A1 | UROTENSIN II RECEPTOR ANTAGONISTS | KINNEY WILLIAM A | 2011-11-03 | — | — | US | disclosed |
| US-8008299-B2 | Urotensin II receptor antagonists | JANSSEN PHARMACEUTICA, N.V. (FR) | 2011-08-30 | — | — | US | disclosed |
| US-8008299-B2 | Urotensin II receptor antagonists | JANSSEN PHARMACEUTICA, N.V. (FR) | 2011-08-30 | — | — | US | disclosed |
| EP-2326644-A1 | UROTENSIN II RECEPTOR ANTAGONISTS | Janssen Pharmaceutica N.V. (BE) | 2011-06-01 | — | — | EP | disclosed |
| WO-2010017105-A1 | UROTENSIN II RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-02-11 | — | — | WO | disclosed |
| US-20100029616-A1 | UROTENSIN II RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-02-04 | — | — | US | disclosed |
| US-20080318973-A1 | Urotensin II receptor antagonists | JANSSEN PHARMACEUTICA, N.V. (BE) | 2008-12-25 | — | — | US | disclosed |
| US-20080318973-A1 | Urotensin II receptor antagonists | JANSSEN PHARMACEUTICA, N.V. (BE) | 2008-12-25 | — | — | US | disclosed |
| WO-2008153902-A2 | UROTENSIN II RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2008-12-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110269768-A1 | UROTENSIN II RECEPTOR ANTAGONISTS | UTS2R, BDKRB2, AGTR2 | UTS2R 1/4885TNF 3039/4885 |
| US-20100029616-A1 | UROTENSIN II RECEPTOR ANTAGONISTS | UTS2R, PLAUR, BDKRB2 | UTS2R 1/4885TNF 2650/4885 |
| US-20080318973-A1 | Urotensin II receptor antagonists | UTS2R, BDKRB2, AGTR2 | UTS2R 1/4885TNF 3039/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.